Panadol Ultra

Active Ingredient:: Paracetamol, Caffeine, Codeine Phosphate Hemihydrate
Origin:: EU

Panadol Ultra (Paracetamol, Caffeine, Codeine Phosphate Hemihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Paracetamol, the active ingredient in Panadol Ultra, is an analgesic/antipyretic presented as a combination tablet for oral use. It treats moderate pain and reduces fever in adults and children when appropriate. GNH India supplies Panadol Ultra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Panadol Ultra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Haleon Czech Republic S.R.O.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Panadol Ultra is an analgesic/antipyretic combination that provides relief across several common pain‑related pathways.

Headache: alleviates pain and improves daily functioning
Dental pain: reduces discomfort after procedures or infections
Musculoskeletal pain: eases aches from strains, sprains and minor injuries
Fever: lowers elevated body temperature in acute febrile states
Menstrual cramps: diminishes cramping pain and associated discomfort

How It Works

Paracetamol acts primarily through central inhibition of cyclooxygenase enzymes, reducing prostaglandin synthesis in the brain to lower pain perception and temperature set‑point. Caffeine enhances analgesic potency by antagonising adenosine receptors, while codeine phosphate hemihydrate is metabolised to morphine, binding opioid μ‑receptors to provide additional central analgesia.

Side Effects

Side effects vary in frequency and severity.

Common Side Effects

Nausea: mild stomach upset that may resolve without treatment
Dizziness: transient light‑headedness, especially on standing
Insomnia: difficulty falling or staying asleep, linked to caffeine
Constipation: reduced bowel movements, typical of opioid‑type agents
Dry mouth: reduced salivation causing throat discomfort

Serious or Rare Side Effects

Hepatotoxicity: liver injury from excessive paracetamol exposure
Respiratory depression: slowed breathing, particularly with high opioid doses
Allergic reactions: rash, itching or swelling indicating hypersensitivity
Seizures: rare neurologic events, often linked to overdose
Severe constipation or bowel obstruction: may require medical attention

Precautions & Warnings

When using Panadol Ultra, consider the following safety measures:

Dose limits: adhere to maximum daily paracetamol intake to avoid liver damage
Alcohol use: limit consumption as it increases hepatotoxic risk
Pre‑existing liver disease: use only under medical supervision
Opioid sensitivity: monitor for signs of sedation or respiratory changes
Pregnancy and breastfeeding: consult a healthcare professional before use
Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight

Avoid Interactions

Panadol Ultra can interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid)

Warfarin: increased bleeding risk due to enhanced anticoagulant effect
Other paracetamol‑containing products: cumulative toxicity risk
CNS depressants: amplified sedation and respiratory depression

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine) may reduce codeine conversion to morphine
Antacids: may affect absorption of caffeine
Diuretics: potential alteration of electrolyte balance

Frequently Asked Questions

Panadol Ultra is a combination analgesic containing paracetamol, caffeine and codeine. It is indicated for the relief of moderate pain such as headache, dental pain, musculoskeletal aches, fever and menstrual‑related discomfort when prescribed by a healthcare professional.

Paracetamol reduces pain and fever by inhibiting central cyclooxygenase enzymes, which lowers prostaglandin production in the brain. Caffeine enhances this effect by blocking adenosine receptors, while codeine is converted to morphine and activates opioid μ‑receptors for additional pain control.

The appropriate dose of Panadol Ultra is determined by the prescribing clinician based on the patient’s age, weight, pain severity and overall health status. Patients should follow the prescriber’s instructions and never exceed the recommended maximum daily amount of paracetamol.

Use of Panadol Ultra during pregnancy or lactation should only occur under medical advice. Paracetamol is generally considered low‑risk, but codeine crosses the placenta and enters breast milk, so a healthcare professional must evaluate the benefit‑risk balance for each individual.

To order, submit an enquiry on the Panadol Ultra product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑ingredient paracetamol, Panadol Ultra adds caffeine for enhanced analgesia and codeine for opioid‑type pain control, offering stronger relief for moderate pain. It differs from NSAIDs by lacking anti‑inflammatory activity and generally has a lower risk of gastrointestinal irritation.

Store Panadol Ultra tablets at temperatures below 25 °C in their original container, protected from moisture and direct sunlight. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Panadol Ultra is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically directed by a healthcare professional.

Serious risks include liver injury from excessive paracetamol, respiratory depression from codeine, severe allergic reactions and, in rare cases, seizures. Patients should seek immediate medical attention if they notice signs such as jaundice, difficulty breathing, or a rash.

Panadol Ultra is contraindicated in individuals with known hypersensitivity to paracetamol, caffeine or codeine, those with severe liver impairment, and patients taking other opioid medications without medical supervision. It should also be avoided in children unless specifically prescribed by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 12 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.